Beacon Capital Management LLC Decreases Stock Position in Pfizer Inc. $PFE

Beacon Capital Management LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,410 shares of the biopharmaceutical company’s stock after selling 465 shares during the period. Beacon Capital Management LLC’s holdings in Pfizer were worth $252,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Capital Advisory Group Advisory Services LLC increased its holdings in Pfizer by 2.9% in the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 388 shares during the period. Trust Co of the South raised its position in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after acquiring an additional 441 shares during the last quarter. Charter Oak Capital Management LLC lifted its stake in shares of Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 444 shares during the period. Ballentine Partners LLC increased its position in Pfizer by 0.5% during the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock valued at $2,260,000 after purchasing an additional 458 shares during the period. Finally, Members Trust Co raised its holdings in Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 467 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on PFE. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Bank of America lifted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Stock Up 0.6%

Shares of NYSE PFE opened at $23.75 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market capitalization of $135.03 billion, a PE ratio of 12.63, a P/E/G ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The business’s fifty day moving average price is $24.55 and its 200-day moving average price is $24.13.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm earned $0.60 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.